DNA Biomed Solns Total Liabilities
DNA Biomed Solns total liabilities. Based on the latest financial reports, DNA Biomed Solns (DNA) has total liabilities worth ILA1.77 Million ILA (≈ $4.76K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check DNA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of DNA Biomed Solns (2005–2024)
Total liabilities of DNA Biomed Solns from 2005 to 2024. This chart illustrates how DNA Biomed Solns's total liabilities have evolved over time, based on quarterly financial data. Explore DNA Biomed Solns strategic investment ratio to see how much of total assets are deployed in long-term investments.
DNA Biomed Solns Competitors by Total Liabilities
The table below lists competitors of DNA Biomed Solns ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aerodrome Group Ltd
TA:ARDM
|
Israel | ILA5.32 Million |
|
Apollo Minerals Ltd
AU:AON
|
Australia | AU$784.61K |
|
Star Comgistic Capital Co Ltd
TW:4930
|
Taiwan | NT$4.92 Billion |
|
Dabomb Protein
TWO:6578
|
Taiwan | NT$106.48 Million |
|
Zaklady Przemyslu Cukierniczego Otmuchow S.A.
WAR:OTM
|
Poland | zł64.22 Million |
|
Memscap Regpt
PA:MEMS
|
France | €7.37 Million |
|
Global SM Tech Limited
KQ:900070
|
Korea | ₩35.90 Billion |
|
JR HOLDING SA BC ZY -10
F:8JA
|
Germany | €52.75 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down DNA Biomed Solns's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DNA Biomed Solns asset portfolio.
Liquidity & Leverage Metrics
DNA Biomed Solns Total Liabilities Ratios Explained
DNA Biomed Solns total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 48.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DNA Biomed Solns's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DNA Biomed Solns (2005–2024)
The table below shows the annual total liabilities of DNA Biomed Solns from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA2.81 Million ≈ $7.55K |
+91.37% |
| 2023-12-31 | ILA1.47 Million ≈ $3.94K |
-21.84% |
| 2022-12-31 | ILA1.88 Million ≈ $5.05K |
+555.75% |
| 2021-12-31 | ILA287.00K ≈ $769.44 |
-97.28% |
| 2020-12-31 | ILA10.54 Million ≈ $28.27K |
+23.30% |
| 2019-12-31 | ILA8.55 Million ≈ $22.92K |
-45.92% |
| 2018-12-31 | ILA15.81 Million ≈ $42.39K |
+75.94% |
| 2017-12-31 | ILA8.99 Million ≈ $24.09K |
-92.61% |
| 2016-12-31 | ILA121.59 Million ≈ $325.97K |
+236.83% |
| 2015-12-31 | ILA36.10 Million ≈ $96.77K |
+30.42% |
| 2014-12-31 | ILA27.68 Million ≈ $74.20K |
+201.03% |
| 2013-12-31 | ILA9.19 Million ≈ $24.65K |
-4.97% |
| 2012-12-31 | ILA9.68 Million ≈ $25.94K |
+51.84% |
| 2011-12-31 | ILA6.37 Million ≈ $17.08K |
-29.79% |
| 2010-12-31 | ILA9.08 Million ≈ $24.33K |
+35.44% |
| 2009-12-31 | ILA6.70 Million ≈ $17.97K |
-16.97% |
| 2008-12-31 | ILA8.07 Million ≈ $21.64K |
+49.13% |
| 2006-12-31 | ILA5.41 Million ≈ $14.51K |
+68.02% |
| 2005-12-31 | ILA3.22 Million ≈ $8.64K |
-- |
About DNA Biomed Solns
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physi… Read more